Introduction {#section6-1470320316666750}
============

Neurodegenerative diseases present an increasingly pressing health issue. Alzheimer's disease (AD) alone affects more than 44 million people globally, with billions of dollars in healthcare costs.^[@bibr1-1470320316666750]^ This is highly critical especially as AD and many other neurodegenerative disorders are still largely idiopathic. Intriguingly, recent research suggests the possible involvement of the brain renin--angiotensin system (RAS) in the aetiology of AD,^[@bibr2-1470320316666750][@bibr3-1470320316666750]--[@bibr4-1470320316666750]^ amyotrophic lateral sclerosis (ALS),^[@bibr5-1470320316666750]^ multiple sclerosis (MS)^[@bibr6-1470320316666750],[@bibr7-1470320316666750]^ and other neurodegenerative conditions.^[@bibr8-1470320316666750],[@bibr9-1470320316666750]^ However, it is not entirely certain whether changes in RAS components in the brain in neurodegenerative diseases are causal or compensatory.

Much of the interest in the involvement of the RAS in neurodegenerative disease focuses on the involvement of angiotensin-converting enzyme (*ACE*) and AD.^[@bibr4-1470320316666750]^ Several reports describe an association of an insertion/deletion (I/D) polymorphism in the *ACE* gene and the incidence of AD.^[@bibr10-1470320316666750][@bibr11-1470320316666750][@bibr12-1470320316666750]--[@bibr13-1470320316666750]^ The II genotype which displays lower *ACE* activity in plasma,^[@bibr14-1470320316666750]^ but not in brain tissue,^[@bibr15-1470320316666750]^ than the DD and ID genotypes was associated with a reduced AD risk compared to the DD genotype.^[@bibr10-1470320316666750][@bibr11-1470320316666750]--[@bibr12-1470320316666750]^ One study has indicated that homozygous DD or II showed a higher AD risk than the ID genotype^[@bibr13-1470320316666750]^ while some other studies have observed no association between the *ACE* I/D polymorphism and AD (see reviews).^[@bibr4-1470320316666750],[@bibr16-1470320316666750]^ The potential for conflicting effects of *ACE* to decrease Aβ toxicity^[@bibr17-1470320316666750]^ contrasted with its ability to increase angiotensin II (Ang II) formation and attendant AT~1~ Ang II receptor mediated neurotoxicities^[@bibr18-1470320316666750]^ could explain the discordant observations.

In addition, there are several single nucleotide polymorphisms (SNPs) in the *ACE* gene that have been studied with respect to a possible association with AD, although the results are ambiguous. The SNPs rs4343, rs4291 and rs1799752 were shown to be associated with AD in Caucasians over 73 years of age,^[@bibr19-1470320316666750]^ and rs4343, rs4291 and rs1800764 were shown to be associated with age of onset of AD.^[@bibr20-1470320316666750]^ The association of the rs4291 SNP with AD was also found for sporadic AD,^[@bibr21-1470320316666750]^ however another meta-analysis did not show an association of rs4343, rs4291 and rs1800764 with late onset AD.^[@bibr2-1470320316666750]^ Four SNPs related to the *ACE* gene and *ACE* protein expression were reported to be associated with an altered risk of AD: rs4968782, rs4343, rs4316 and rs4459609.^[@bibr22-1470320316666750]^ The authors suggest that increased *ACE* activity in the brain clears Aβ42 decreasing AD risk. However, this runs contrary to studies suggesting that *ACE* inhibitors reduce AD risk.^[@bibr23-1470320316666750]^ Of note, Qiu et al.^[@bibr23-1470320316666750]^ only saw a reduction in AD risk with *ACE* inhibitors in populations that did not carry the Apo E4 allele that is associated with an increased risk of AD. However, in a subsequent study of an elderly population, an increase in AD risk was observed in ApoE4 allele carriers treated with *ACE* inhibitors.^[@bibr24-1470320316666750]^

Indeed, while the RAS works primarily to regulate cardiovascular functions, the receptors and hormones that make up the RAS in the brain may play roles at both the local and cellular level,^[@bibr25-1470320316666750]^ affecting not only autonomic control of blood pressure but also neuroinflammation, neurodegeneration and/or neuroprotection. This study attempts to evaluate the relationship between the expression of the genes encoding components of the RAS and related hormones (as well as the SNPs in those genes) and the occurrence of several neurodegenerative diseases through the incorporation and analysis of publicly available published datasets from genome-wide association studies (GWASs) and gene expression data in relation to neurodegenerative diseases.

Methods {#section7-1470320316666750}
=======

The study consisted of *in silico* analyses of five neurodegenerative diseases: narcolepsy, Parkinson's disease, AD, ALS and MS. For each disease, a meta-analysis of GWASs and a survey of gene expression data were completed for several RAS-related genes (see [Table 1](#table1-1470320316666750){ref-type="table"}). The GWASs that were included in the meta-analysis were sourced from \<[www.gwascentral.org](http://www.gwascentral.org)\>. The number of studies that were included varied for each disease, but each represented at least several hundred SNPs found to be significant (see [Table 2](#table2-1470320316666750){ref-type="table"}).

###### 

Renin--angiotensin system component genes and functionality of the components in relation to neurodegenerative conditions.

![](10.1177_1470320316666750-table1)

  Gene symbol   Name of protein encoded by gene                                    Function                                              Relation to neurodegeneration                                                              References
  ------------- ------------------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *ACE*         Angiotensin I converting enzyme (*ACE*)                            Converts Ang I to Ang II                              Forms Ang II, degradation of Abeta(1-42), hyperphosphorylation of tau                      ^[@bibr32-1470320316666750][@bibr33-1470320316666750][@bibr34-1470320316666750]--[@bibr35-1470320316666750]^
  *ACE2*        Angiotensin I converting enzyme 2 (*ACE2*)                         Converts Ang II to Ang (1--7)                         Ang (1--7) is neuroprotective, decreases Ang II formation                                  ^[@bibr18-1470320316666750],[@bibr36-1470320316666750][@bibr37-1470320316666750][@bibr38-1470320316666750]--[@bibr39-1470320316666750]^
  *AGT*         Angiotensinogen (serpin, clade A, member 8) (*AGT*)                Unknown                                               Precursor for all angiotensin peptides                                                     ^[@bibr40-1470320316666750]^
  *AGTR1*       Angiotensin II receptor, type 1 (AT-1R)                            GPCR for Ang II-mediates most Ang II/III effects      Produces reactive oxygen species and inflammation in response to Ang II/III                ^[@bibr29-1470320316666750],[@bibr41-1470320316666750][@bibr42-1470320316666750][@bibr43-1470320316666750][@bibr44-1470320316666750]--[@bibr45-1470320316666750]^
  *AGTR2*       Angiotensin II receptor, type 2 AT-2R)                             GPCR for Ang II mediates effects counteracting AT1R   Neuroprotective memory impairment                                                          ^[@bibr9-1470320316666750],[@bibr46-1470320316666750],[@bibr47-1470320316666750]^
  *ATP6AP2*     ATPase, H+ transporting, lysosomal accessory protein 2             (Pro)renin receptor                                   Activates prorenin, increases Ang I formation, ERK1/2 signaling, vacuolar H^+^ transport   ^[@bibr26-1470320316666750],[@bibr48-1470320316666750],[@bibr49-1470320316666750]^
  *CMA1*        Chymase 1, mast cell                                               Converts Ang I to Ang II                              Forms Ang II which acts on AT                                                              ^[@bibr50-1470320316666750][@bibr51-1470320316666750]--[@bibr52-1470320316666750]^
  *LNPEP*       Leucyl-cystinyl aminopeptidase, insulin regulated aminopeptidase   AT4 receptor                                          Possible involvement in memory formation and cognition, long-term potentiation             ^[@bibr8-1470320316666750],[@bibr53-1470320316666750],[@bibr54-1470320316666750]^
  *MAS1*        *MAS1* proto-oncogene, G protein-coupled receptor                  Receptor for Ang (1--7)                               Inhibits neurodegeneration and inflammation in response to Ang (1--7)                      ^[@bibr37-1470320316666750],[@bibr38-1470320316666750],[@bibr55-1470320316666750][@bibr56-1470320316666750]--[@bibr57-1470320316666750]^
  *MME*         Neprilysin, neutral endopeptidase                                  Metabolises Ang I to Ang (1--7)                       Ang (1--7) is neuroprotective, decreases Ang II formation                                  ^[@bibr37-1470320316666750],[@bibr38-1470320316666750],[@bibr58-1470320316666750],[@bibr59-1470320316666750]^
  *PRCP*        Prolylcarboxypeptidase (angiotensinase C)                          Converts Ang II to Ang (1--7)                         Ang (1--7) is neuroprotective, decreases Ang II formation                                  ^[@bibr37-1470320316666750],[@bibr38-1470320316666750],[@bibr60-1470320316666750]^
  *PREP*        Prolyl endopeptidase                                               Converts Ang II to Ang (1--7)                         Ang (1--7) is neuroprotective, decreases Ang II formation                                  ^[@bibr37-1470320316666750],[@bibr38-1470320316666750],[@bibr61-1470320316666750]^
  *REN*         Renin                                                              Enzyme which converts *AGT* to Ang I                  Increases Ang II, signals via (Pro)renin receptor                                          ^[@bibr62-1470320316666750][@bibr63-1470320316666750][@bibr64-1470320316666750]--[@bibr65-1470320316666750]^
  *THOP*        Thimet oligopeptidase                                              Metabolises Ang I to Ang (1--7)                       Ang (1--7) is neuroprotective, decreases Ang II formation                                  ^[@bibr37-1470320316666750],[@bibr38-1470320316666750],[@bibr66-1470320316666750]^

###### 

Genome-wide association studies included in meta-analysis.

![](10.1177_1470320316666750-table2)

  Disease                         Studies by GWAS central identifier   No. of SNPs
  ------------------------------- ------------------------------------ -------------
  Parkinson's disease             HGVST1732                            3
  HGVST883                        3                                    
  HGVST816                        10                                   
  HGVST676                        3                                    
  HGVST664                        3                                    
  HGVST599                        4                                    
  HGVST434                        10                                   
  HGVST425                        4                                    
  HGVST392                        195,214 (top 50)                     
  HGVST6                          792,112 (top 50)                     
  Alzheimer's disease             HGVST1736                            1
  HGVST990                        11                                   
  HGVST938                        18                                   
  HGVST845                        5                                    
  HGVST799                        5                                    
  HGVST762                        4                                    
  HGVST687                        38                                   
  HGVST553                        1                                    
  HGVST546                        2                                    
  HGVST51                         411,838 (top 50)                     
  HGVST318                        1711 (top 50)                        
  HGVST351                        1                                    
  Narcolepsy                      HGVST596                             2
  HGVST115                        244,737 (top 50)                     
  HGVST159                        1                                    
  Amyotrophic lateral sclerosis   HGVST1692                            2
  HGVST601                        2                                    
  HGVST348                        8                                    
  HGVST375                        7184 (top 50)                        
  HGVST29                         512,009 (top 50)                     
  HGVST38                         137 (top 50)                         
  HGVST65                         512,763 (top 50)                     
  HGVST76                         350 (top 50)                         
  HGVST127                        16                                   
  HGVST162                        1                                    
  HGVST175                        3                                    
  Multiple sclerosis              HGVST1590                            16
  HGVST1273                       1                                    
  HGVST994                        19                                   
  HGVST901                        50                                   
  HGVST785                        6                                    
  HGVST719                        3                                    
  HGVST536                        4                                    
  HGVST524                        2                                    
  HGVST503                        2                                    

The SNPs present in various RAS-related genes were sourced from the UCSC Gene Browser, which in turn sources its data from RefSeq. These SNPs were then cross-referenced with the collations of GWAS data. Any significant SNPs would ideally match multiple times to indicate a repeated finding of significance. The gene expression data were sourced from NCBI's GEO datasets, and reflected several different cell types (see [Table 3](#table3-1470320316666750){ref-type="table"}). These datasets were analysed through both the built-in GEO2R utility and through visual interpretation of graphs of the varying levels of gene expression. The GEO2R utility performed statistical calculations automatically, which assisted in identifying significant differences in expression.

###### 

List of data used in expression comparison in neurodegenerative diseases.

![](10.1177_1470320316666750-table3)

  Disease                         Study type                Datasets/studies by NCBI identifier   No. of cases   No. of controls                                                              Significant (*P*\<0.05)[\*](#table-fn1-1470320316666750){ref-type="table-fn"} Increase ↑ or decrease ↓ in RAS-related gene expression
  ------------------------------- ------------------------- ------------------------------------- -------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  Parkinson's disease             Lymphoblast               GSE20153                              8              8                                                                            *ATP6AP2* ↓
  Putamen                         GSE20291                  20                                    15             *ATP6AP2* ↓, *AGT* ↓, *AGTR1* ↓, *MAS1* ↓, *LNPEP* ↓, *AGTR2* ↓, *ACE2* ↓,   
  Prefrontal area 9               GSE20168                  15                                    14             *ACE* ↑, *ACE2* ↑                                                            
  Substantia nigra                GSE7621                   16                                    9              ***AGTR1* ↓**, *LNPEP* ↓                                                     
                                  GSE20292                  11                                    18             None present (*P*\>0.05)                                                     
  Alzheimer's disease             Severity                  GSE1297                               22             9                                                                            ***AGTR1* ↑**, *ACE2* ↑
  Neurofibrillary tangles         GSE4757                   10                                    10             *MAS1* ↑                                                                     
  Hippocampal grey matter         GSE28146                  22                                    8              *ATP6AP2* ↓                                                                  
  Whole brain                     GSE36980                  32                                    47             ***AGT* ↓**, ***ATP6AP2* ↓**, ***MAS1* ↓**, *PREP* ↓, *LNPEP* ↓              
  Narcolepsy                      Whole blood               GSE21592                              10             10                                                                           *LNPEP* ↑
  Amyotrophic lateral sclerosis   Spinal cord grey matter   GSE833                                7              4                                                                            *MAS1* ↓
  Muscle biopsy                   GSE3307                   9                                     14             *PRCP* ↓, *PREP* ↓                                                           
  Multiple sclerosis              Brain                     GSE5839                               3              1                                                                            *AGTR2* ↑, *LNPEP* ↑
                                  Mononuclear blood cells   GSE21942                              14             15                                                                           ***ATP6AP2* ↓**, *LNPEP* **↓**, ***MME* ↑**, *PREP*↓

Genes in bold type were significant after Bonferroni correction for multiple comparisons.

The data were corrected for multiple comparison using the Bonferroni multiple comparisons test with α=0.05 and *m=*14 (14 genes were studied). This resulted in a corrected significance threshold of 0.0036. However, several different signals which were observed to be significantly associated by individual analysis did not survive the correction for multiple comparisons. Because this correction placed such a high stringency on the analyses, we report all data that showed a significant association that did not survive the multiple comparison in [Table 2](#table2-1470320316666750){ref-type="table"}, but place our focus on the associations that remained statistically significant after the multiple comparison correction: i.e. *p*\<0.0036, which is indicated in bold font in [Table 2](#table2-1470320316666750){ref-type="table"}.

We used random-effect meta-analyses as the primary method of discovery and SPSS (v. 17) to do a secondary meta-analysis for heterogeneity. This second analysis is useful to estimate the possible effect of study heterogeneity on results and qualitatively to infer the effect of study heterogeneity on generalisability for similar sample series. We calculated χ^2^ tests for heterogeneity (Cochran's Q) with SPSS and we generated I^2^ estimates using the equation:

$$I^{2} = \ 100\%\ *\ \left( {Q - df} \right)/Q$$

where *Q* is the Cochran's *Q* test estimate, and *df* is the degrees of freedom=13.

Results {#section8-1470320316666750}
=======

In our current analysis using the publicly available datasets for GWAS, we found no SNP matches for any of the RAS-related genes in association with AD or any other neurodegenerative diseases.

We next examined genome-wide transcriptional studies to determine if there was any correlation between mRNA levels of the RAS components and neurodegenerative diseases. Gene expression data showed multiple significant (*p*\<0.05, after correction for multiple comparisons to a significance level of *p*\<0.0036) differences in RAS-related gene expression. The most significant association overall was the decreased expression of the gene *ATP6AP2*, which encodes the (pro)renin receptor^[@bibr26-1470320316666750]^ in mononuclear blood cells of MS patients (*p*=3.52E-9). Expression of the *ATP6AP2* gene was also significantly decreased in the brains of AD patients (*p*\<0.000403). Another gene that exhibited connections with neurodegenerative diseases was *AGTR1*, which encodes the primary Ang II receptor subtype (AT~1~). Expression of *AGTR1* was decreased in postmortem substantia nigra samples of Parkinson's disease patients (*p*=1.56E-5) and showed a near significant positive correlation with AD severity (*p*=0.00394). Expression of the gene *LNPEP* (which encodes cysteinyl aminopeptidase, a protein that binds a 6 amino acid carboxy terminal fragment of Ang II and has an alternative nomenclature as the angiotensin IV (AT~4~) receptor was significantly increased (*p*=0.000039) in mononuclear blood cells from MS patients and showed a trend towards increased expression with narcolepsy (*p*=0.00743). Expression of *AGT* and *MAS1* were decreased in Alzheimer's diseased brains: (*p*=7.93E-6) and (*p*=0.000521). Expression of *MME*, which encodes neprilysin, also known as neutral endopeptidase, was increased in mononuclear blood cells of MS patients (*P*=0.0023). Several other RAS genes were found to be significant for one or more neurodegenerative diseases, but did not survive the correction for multiple comparisons ([Table 2](#table2-1470320316666750){ref-type="table"}). In sum, various RAS genes appear to be expressed at significantly different levels in samples taken from subjects with neurodegenerative diseases.

We also conducted Cochran's *Q* test for heterogeneity and calculated the I^2^ value. The Cochran's *Q* test for χ^2^(14) was 24.1, *p*=0.03. The I^2^ value was 46.0±4.6%, indicating low levels of heterogeneity in the results of the studies considered in this analysis. However, this level of heterogeneity is not unexpected because the same pooled treatment estimate for the entire study dataset was considered with a random effects model. The heterogeneity present in the study could also be attributed to the different types of tissues included in the study along with the use of different types of genomic studies with various types of genome-wide analysis technological platforms.

Discussion {#section9-1470320316666750}
==========

There has been considerable speculation regarding the involvement of the brain RAS in neurodegenerative disease,^[@bibr21-1470320316666750],[@bibr27-1470320316666750]^ however there has not been a systematic survey of all the current GWASs evaluating all genetic alterations in the genes of the various proteins that comprise the RAS, including newly discovered elements such as the prorenin receptor, *ACE*-2, and other enzymes that metabolise angiotensin peptides.^[@bibr28-1470320316666750]^ There was no evidence of SNPs in any RAS-associated genes surveyed that are significantly associated with any of the neurodegenerative diseases analysed in this study. However, this analysis is based upon publicly available databases that were hosted at <http://www.gwascentral.org>, and does not preclude the discovery of significant RAS-associated gene alteration associations in proprietary databases, or specific ethnic group subsets, or in more comprehensive datasets that are yet to be populated with larger numbers of patients.

![Potential Mechanistic Links Between Renin-Angiotensin System and Neurodegeneration.](10.1177_1470320316666750-fig1){#fig1-1470320316666750}

In contrast, the gene expression data demonstrate a strong link between RAS gene expression and several neurodegenerative diseases. Of note, the two components of the RAS which show the greatest association with neurodegenerative diseases are receptors for RAS hormones: the AT~1~ receptor subtype for Ang II (the primary hormone and pathogenic component of the RAS) and the prorenin receptor, which is now recognised to signal via mitogen activated protein kinases (MAPKs) in response to prorenin and renin, thereby paralleling some of the pathophysiological effects of Ang II at the AT~1~ receptor.^[@bibr26-1470320316666750]^ It is noteworthy that the AT~1~ receptor signals via the activation of nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase, thereby generating reactive oxygen species^[@bibr29-1470320316666750],[@bibr30-1470320316666750]^ creating oxidative stress in neurons which could contribute to the neuronal cell death associated with neurodegenerative diseases. Indeed, *AGTR1* expression has been linked to nucleic acid oxidation in models of Parkinson's disease;^[@bibr31-1470320316666750]^ wherein 8-hydrodeoxyguanosine has been reported to be elevated under the influence of *AGTR1* expression in Parkinson's disease. This could be a possible contributing mechanism for the action of the RAS in neurodegenerative disease; however, a causal relationship is still not established.

While the gene expression data demonstrate a strong association between RAS gene expression and neurodegenerative diseases, some concerns must still be addressed. One of the expression datasets used as a basis for comparison, GSE5839, consisted of only four samples, which may have limited its ability to demonstrate the significance of the RAS's connection to MS in the general population.

It is noteworthy to mention that there was an inherent low level of heterogeneity in our study results that could be attributed to the different types of tissues included in the study, along with the use of different types of genomic studies with various types of genome-wide analysis technological platforms.

Despite the study's limitations, the differences in the expression of RAS genes in neurodegenerative diseases are still notable enough to warrant further study. A reasonable next step would be to conduct in vivo studies on animal models of various neurodegenerative diseases in order to determine if the differences in gene expression observed here are translated into differences in functional expression of these receptor proteins. Studies using AT~1~ receptor blockers and renin receptor antagonists could also be conducted in order to test whether activation of these receptors whose gene expression is increased causes increased oxidative stress or other pathophysiological effects that aggravate or cause characteristic neurodegenerations associated with specific neurodegenerative diseases.
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